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Abstract:
Infection of cattle with Leptospira borgpetersenii serovar Hardjo can have
negative impacts on the cattle industry and pose the risk of transmission
to other mammals, including humans. Current commercial vaccines used
to protect against Leptospira serovar Hardjo are ineffective at providing
long-term immunity, and a more cell-mediated immune response is
thought to be necessary for lasting protection. IgG1 and IgG2 levels can
be indicative of what type of a T cell response predominates; in a cell-
mediated type 1 (Th1) immune response, interferon-ү (IFN-ү) secreted
from helper T cells will stimulate B cells to class-switch to manufacture
and secrete IgG2. In a humoral type 2 (Th2) immune response, helper T
cells secrete interleukin-4 (IL-4) that stimulates B cells to class-switch to
manufacture and secrete antibodies of the IgG1 isotype. In this study, a
novel vaccine formulated with an oil-based adjuvant was shown to induce
a stronger and more balanced cell-mediated response in comparison with
current commercial serovar Hardjo vaccines. This was demonstrated by
analyzing antibody levels in response to vaccination and challenge with
Leptospira serovar Hardjo.
Background:
• Leptospirosis is thought to be the most widespread zoonotic disease in
the world.
• Chronic infection by Leptospira serovar Hardjo in cattle results in
reproductive problems that can have detrimental effects on the cattle
industry.
• Infected cattle also pose the risk of transmitting the disease to other
mammals, including humans.
• Current commercial monovalent vaccines against Leptospira serovar
Hardjo are inadequate at preventing chronic infection in cattle.
• Current monovalent vaccines contain alum adjuvant that induces a
primarily humoral Th2 response.
• An oil-based adjuvant, Montanide ISA 201 VG, is thought to induce a
more cell-mediated Th1 response when used in vaccines.
• It is thought that a stronger and more balanced humoral and cell-
mediated response is needed to provide long-term immunity.
• In a cell-mediated Th1 response, IFN-ү secreted from helper T cells
stimulates B cell class-switching to secrete IgG2. In this way, IgG2
antibody levels can be indicative of a Th1 response.
• In a humoral Th2 response, IL-4 secreted from helper T cells stimulates
B cell class-switching to secrete IgG1. In this way, IgG1 antibody levels
can be indicative of a Th2 response.
Experimental Design:
Week 0 4 13 32 4 10
Vaccines:
• Seppic Bacterin
• Novel vaccine
• 5x109 formalin fixed L. borgpetersenii Hardjo 203 per mL suspended
1:1 in Montanide ISA 201 VG (Seppic, Fairfield NJ)
• Spirovac (Pfizer, New York NY)
• Commercial monovalent vaccine
• Inactivated L. borgpetersenii Harjo in alum adjuvant
• Leptavoid (Intervet, UK)
• Commercial monovalent vaccine
• Inactivated L. interrogans Hardjo 204 in alum adjuvant
• Adjuvant Only
• Control group
• 1:1 alum adjuvant (Alhydrogel, InvivoGen, San Diego CA) and
Montanide ISA 201 VG adjuvant
Blood CollectionVaccination Challenge
Serum Antibody Evaluation by ELISA: Preliminary Conclusions:
• The novel vaccine made using Montanide ISA 201 VG oil-based
adjuvant induced a stronger and more balanced cell-mediated Th1
response in comparison the two commercial monovalent vaccines.
• Commercial vaccines showed no indication of successfully
stimulating an immune response.
• An expected increase in IgM in response to vaccination and
challenge was not observed.
• A possible correlation may exist between non-vaccination and
increased levels of IgA in response to Leptospira infection.
• 24 mixed breed heifers ~18 months of age were divided into 4
vaccine groups (n=6 per group).
• Animals were vaccinated subcutaneously with 2 mL of their respective
vaccine. An identical booster dose was administered 4 weeks later.
• Blood was collected throughout the study via jugular venipuncture.
Blood sera was separated via centrifugation and stored at -20°C.
• Animals were challenged over 3 consecutive days. 5x106 L.
borgpetersenii Hardjo 203 in 1 mL PBS was administered to each
conjunctiva (eye) and intravaginally per day.
• ELISA was used to detect sera antibody levels. Sera was serially
diluted and tested for L. borgpetersenii Hardjo 203-specifc antibodies
of IgG1, IgG2, IgM, and IgA.
• Optical density (OD) values were used to determine titers. Titers are
expressed as the reciprocal of the highest dilution with an OD value
greater than or equal to the determined background level.
• Two-way analysis of variance (ANOVA) was performed using time
and vaccine group as factors along with Tukey pair-wise comparison
post-tests (GraphPad Software, La Jolla CA).
Comparison of IgG Isotypes:
Comparison of titers of IgG1 and IgG2 serum antibodies in the Seppic Bacterin
vaccine group showed that there was no significant difference (P < 0.05) in titers
between the two isotypes at identical time intervals. These results differ from those
found using commercial monovalent vaccines, in which IgG1 levels predominated
over IgG2, indicating lack of a cell-mediated Th2 response.
Sera collected throughout the study was evaluated using sheep anti-
bovine IgG1. Significant increases (P < 0.05) in IgG1 were observed in
the Seppic Bacterin group in comparison with Adjuvant Only control
group titers at identical time intervals (†) as well as in comparison to the
Seppic Bacterin group Week 0 Pre-Challenge titer (*). IgG1 levels
peaked at Week 13 Pre-Challenge in response to vaccination and Week
4 Post-Challenge in response to challenge. No significant patterns of
increase were detected in any other vaccine groups in response to
vaccination or challenge.
Sera collected throughout the study was evaluated using sheep anti-
bovine IgG2. Significant increases (P < 0.05) in IgG2 were observed in
the Seppic Bacterin group in comparison with Adjuvant Only control
group titers at identical time intervals (†) as well as in comparison to the
Seppic Bacterin group Week 0 Pre-Challenge titer (*). IgG2 levels peaked
at Week 13 Pre-Challenge in response to vaccination and showed
relatively identical levels at Week 4 and 10 Post-Challenge in response to
challenge. No significant patterns of increase were detected in any other
vaccine groups in response to vaccination or challenge.
Sera collected throughout the study was evaluated using goat anti-
bovine IgM. Background levels for IgM were much higher than in other
ELISA assays. No well characterized patterns of significance (P < 0.05)
in comparison to Adjuvant Only control group titers at identical time
intervals (†) or in comparison to respective vaccine group Week 0 Pre-
Challenge titers (*) were detected for any of the vaccine groups.
Sera collected throughout the study was evaluated using sheep anti-
bovine IgA. In Week 4 and 10 Post-Challenge, results indicated a
significant increase (P < 0.05) in IgA in the Adjuvant Only control group
in comparison to titers of the other three vaccine groups at identical time
intervals (†). Comparisons of titers to the Adjuvant Only control group
Week 0 Pre-Challenge titer (*) showed no well characterized patterns.
Discussion:
• Characterization of cell populations, especially IFN-ү and IL-4
producing cells, would be beneficial in better determining the exact
mechanisms needed to induce a balanced response.
• Duration of immunity studies should be conducted to determine
potential long-term efficacy of the novel vaccine.
• Lack of a well characterized IgM response may be attributed to
sample collection intervals being too widely dispersed, or it could be
an indication that T cell activation to form helper T cells was adequate
since large amounts of IgM do not require helper T cells.
• Results indicating higher IgA titers in nonvaccinated animals are
currently being investigated as a potential diagnostic marker for
Leptospira infection.
• High IgA titers in nonvaccinated animals may be due to kidney
damage from infection that causes local IgA to leak into the
bloodstream, or it may be due to vaccinated animals being able to
class-switch to IgA because of previous irreversible switching to
produce IgG in response to vaccination.
Acknowledgements:
Thanks to: David Alt, Richard Hornsby, and Ami Frank for providing laboratory assistance, cultures
microscopy images, and sample collection; the NADC animal care staff for excellent animal care; and Judy
Stabel and Donald Beitz for project supervision.Leptospira viewed under transmission electron microscopy.
